Hinge Bio Shares Encouraging Clinical Data for HB2198, a Novel B-Cell Depleting Agent for Treating Autoimmune Disease, at ACR Convergence 2026

November 9, 2026

Hinge Bio to Present Latest Results of HB2198, a Novel B-Cell Depleting Agent for Treating Autoimmune Disease, at ACR Convergence 2026

November 2, 2026

Hinge Bio Announces First Subject Dosed in Phase 1 Trial of HB2198, a Novel B cell Depleting Agent, for Treating Autoimmune Disease

April 14, 2026

Hinge Bio Announces FDA Clearance of Investigational New Drug Application for HB2198, a Novel B cell-Depleting Agent, for Patients with Systemic Lupus Erythematosus and Lupus Nephritis

October 13, 2025

Hinge Bio Announces License and Collaboration with Kyorin Pharmaceutical Co., Ltd. for the Development and Commercialization of HB2198 in Japan for Autoimmune Diseases

September 30, 2025

Hinge Bio Expands Leadership Team to Drive Clinical Development of GEM-DIMER™ Programs and Announces Publication in Scientific Reports

September 4, 2025

Hinge Bio Raises $30 Million Series A’ Financing to Develop Next-Generation Therapies via its Proprietary GEM-DIMER Platform

January 15, 2025

Hinge Bio Presents Preclinical Data from its GEM-DIMER™ Programs Targeting B Cell Depletion at the American College of Rheumatology (ACR) Convergence 2024

November 14, 2024

Hinge Bio, Inc. Chief Scientific Officer, Daniel Capon, Ph.D., to Present its GEM-DIMER™ Platform Technology at the University of Oxford, Kennedy Institute of Rheumatology’s Annual Translational Research Conference

August 14, 2024

Hinge Bio Presents Preclinical Data from its GEM-DIMER Program Targeting B Cell Depletion at the American Association for Cancer Research (AACR) Annual Meeting 2024

April 8, 2024